{{Drugbox
| verifiedrevid = 460777963
| IUPAC_name = 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5''H''-benzo[5,6]cyclohepta[1,2-b]pyridine
| image = Desloratadine.svg
| width = 222
| image2 = Desloratadine2.png

<!--Clinical data-->
| tradename = Clarinex (US), Aerius (EU), others
| Drugs.com = {{drugs.com|monograph|desloratadine}}
| MedlinePlus = a602002
| licence_EU = Aerius
| licence_US = Desloratadine
| pregnancy_AU = B1
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = S2
| legal_UK = POM
| legal_US = Rx-only
| legal_CA = OTC
| legal_status =  
| routes_of_administration = Oral (tablets, solution)

<!--Pharmacokinetic data-->
| bioavailability = Rapidly absorbed
| protein_bound = 83 to 87%
| onset = within 1 hour
| metabolism = Liver
| metabolites = 3-Hydroxydesloratadine
| duration_of_action = up to 24 hours
| elimination_half-life = 27 hours
| excretion = 40% as conjugated metabolites into urine<br />Similar amount into the feces

<!--Identifiers-->
| IUPHAR_ligand = 7157
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 100643-71-8
| ATC_prefix = R06
| ATC_suffix = AX27
| PubChem = 124087
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00967
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 110575
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = FVF865388R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03693
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 291342
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1172

<!--Chemical data-->
| C=19 | H=19 | Cl=1 | N=2
| molecular_weight = 310.82 g/mol
| smiles = Clc4cc2c(C(/c1ncccc1CC2)=C3/CCNCC3)cc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JAUOIFJMECXRGI-UHFFFAOYSA-N
}}

'''Desloratadine''' (trade name '''Clarinex''' in the US and '''Aerius''' in Europe) is a tricyclic [[Antihistamine|H<sub>1</sub>-antihistamine]] that is used to treat [[allergy|allergies]].  It is an [[active metabolite]] of [[loratadine]].

== Medical uses ==
Desloratadine is used to treat [[allergic rhinitis]] and [[nasal congestion]].<ref name=AFP2003>{{cite journal | author=See S | title=Desloratadine for allergic rhinitis | journal=Am Fam Physician | volume=68 | issue=10 | pages=2015–6 | year=2003 | pmid=14655812 | url=http://www.aafp.org/afp/20031115/steps.html}}</ref>  It is the major [[metabolite]] of [[loratadine]] and the two drugs are similar in safety and effectiveness.<ref name=AFP2003/> Desloratadine is available in many dosage forms and under many trade names worldwide.<ref>Drugs.com [http://www.drugs.com/international/desloratadine.html Desloratadine entry at drugs.com international] Page accessed May 4, 2015</ref>

An emerging indication for desloratadine is in the treatment of [[acne]], as an inexpensive adjuvant to isotretinoin and possibly as maintenance therapy or monotherapy.<ref name=JEADV2014>{{cite journal |vauthors=Lee HE, Chang IK, Lee Y, Kim CD, Seo YJ, Lee JH, Im M | title=Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study | journal=J Eur Acad Dermatol Venereol | volume=28 | issue=12 | pages=1654–60 | year=2014 | pmid=25081735 | url=http://onlinelibrary.wiley.com/doi/10.1111/jdv.12403/full | doi=10.1111/jdv.12403}}</ref><ref name=DC2016>{{cite journal | author=Layton AM | title=Top Ten List of Clinical Pearls in the Treatment of Acne Vulgaris | journal=Dermatol Clin | volume=34 | issue=2 | pages=147–57 | year=2016 | pmid=27015774 | url=http://www.sciencedirect.com/science/article/pii/S0733863515001473 | doi=10.1016/j.det.2015.11.008}}</ref>

== Side effects ==
The most common side-effects are [[fatigue (medical)|fatigue]], dry mouth, and headache.<ref name=AFP2003/>

== Interactions ==
A number of drugs and other substances that are prone to interactions, such as [[ketoconazole]], [[erythromycin]] and [[grapefruit juice]], have shown no influence on desloratadine concentrations in the body. Desloratadine is judged to have a low potential for interactions.<ref name="EPAR">{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000313/WC500025540.pdf|title=Aerius: EPAR – Product Information|publisher=[[European Medicines Agency]]|date=2017-06-07}}</ref>

== Pharmacology ==
=== Mechanism of action ===
Desloratadine is a selective H<sub>1</sub>-[[antihistamine]] which functions as an [[inverse agonist]] at the [[HRH1|histamine H<sub>1</sub> receptor]].<ref name="Desloratedine">{{cite journal | vauthors = Canonica GW, Blaiss M | title = Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence | journal = World Allergy Organ J | volume = 4 | issue = 2 | pages = 47–53 | year = 2011 | pmid = 23268457 | pmc = 3500039 | doi = 10.1097/WOX.0b013e3182093e19 | url = }}</ref>

At very high doses, is also an [[receptor antagonist|antagonist]] at various subtypes of the [[muscarinic acetylcholine receptor]]s. This effect is not relevant for the drug's action at therapeutic doses.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000313/WC500022748.pdf|title=Aerius: EPAR – Scientific Discussion|publisher=[[European Medicines Agency]]|date=2006-04-03}}</ref>

=== Pharmacokinetics ===
Desloratadine is well absorbed from the gut and reaches highest [[blood plasma]] concentrations after about three hours. In the bloodstream, 83 to 87% of the substance are bound to [[plasma protein]]s.<ref name="EPAR" />

An unidentified enzyme metabolizes it to 3-hydroxydesloratadine, which is then [[glucuronidation|glucuronidized]]. Both desloratadine and 3-hydroxydesloratadine are eliminated via urine and feces with a [[biological half-life|half-life]] of 27 hours.<ref name="EPAR" /><ref name="Drugs.com">[[Drugs.com]]: Desloratadine {{Drugs.com|monograph|desloratadine}}.</ref>

It exhibits only peripheral activity since it does not readily cross the [[blood-brain barrier]]; hence, it does not normally cause [[drowsiness]] because it does not readily enter the [[central nervous system]].<ref>{{cite journal | vauthors=Mann R, Pearce G, Dunn N, Shakir S | title=Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice | journal=BMJ | volume=320 | issue=7243 | pages=1184–6 | year=2000 | pmid=10784544 | url=http://bmj.bmjjournals.com/cgi/content/full/320/7243/1184 | doi=10.1136/bmj.320.7243.1184 | pmc=27362}}</ref>

[[File:3-Hydroxydesloratadine skeletal.svg|thumb|left|3-Hydroxydesloratadine, the main [[metabolite]]]]
{{clear left}}

=== Pharmacogenomics ===
2% of [[Caucasian race|Caucasian people]] and 18% of black people are desloratadine [[poor metabolizer]]s. In these people, the drug reaches threefold highest plasma concentrations six to seven hours after intake, and has a half-life of about 89 hours. However, the safety profile for these subjects is not worse than for extensive (normal) metabolizers.<ref name="EPAR" /><ref name="Drugs.com" />

== See also ==
* [[Benzocycloheptenes]]
* [[Azatadine]]

==References==
<references />

{{Antihistamines}}
{{Histaminergics}}
{{Tricyclics}}

[[Category:Benzocycloheptapyridines]]
[[Category:Chloroarenes]]
[[Category:H1 receptor antagonists]]
[[Category:Human drug metabolites]]
[[Category:Peripherally selective drugs]]
[[Category:Piperidines]]
[[Category:Schering-Plough]]